Clinical Trials Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Feb 28, 2015; 21(8): 2433-2442
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2433
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 MYC and BCL-2 expression in primary gastrointestinal diffuse large B-cell lymphoma by immunohistochemistry (magnification × 200 and × 400, respectively).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 mRNA expression of MYC and BCL-2 in primary gastrointestinal diffuse large B-cell lymphoma patients.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Survival curves for the entire population of patients with primary gastrointestinal diffuse large B-cell lymphoma. A: Progression-free survival (PFS); B: Overall survival (OS).
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Survival analysis of primary gastrointestinal diffuse large B-cell lymphoma. The effects of age (A), Lugano stage (B), IPI score (C), the expression of BCL-2 protein (D), and treatment (E) on progression-free survival (PFS); And the effects of Lugano stage (F), IPI score (G) and BCL-2 protein expression (H) on overall survival (OS). ST: Surgery; CT: Chemotherapy; RT: Radiotherapy; IPI: International prognostic index.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Kaplan-Meier curves represent overall survival (OS) (A) and progression-free survival (B) according to presence of MYC and BCL-2 protein expression. OS: Overall survival; PFS: Progression-free survival.